Neurogene Inc Cash Flow Conversion Efficiency
Neurogene Inc cash flow conversion efficiency. Based on the latest financial reports, Neurogene Inc (NGNE) has a cash flow conversion efficiency ratio of -0.110x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-26.12 Million) by net assets ($237.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Neurogene Inc (2011–2025)
Cash flow conversion efficiency of Neurogene Inc from 2011 to 2025. This chart illustrates how Neurogene Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View NGNE live share price for real-time trading data and today's change.
Neurogene Inc Cash Flow Conversion Ratio Explained
Neurogene Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Neurogene Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neurogene Inc ranked by their cash flow conversion efficiency. Also see Neurogene Inc (NGNE) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SENCO GOLD LTD
NSE:SENCO
|
-0.133x |
|
Loctek Ergonomic Technology Corp Class A
SHE:300729
|
0.095x |
|
Puyang Refractories Group Co Ltd
SHE:002225
|
0.011x |
|
Semen Indonesia Persero Tbk
JK:SMGR
|
0.012x |
|
Yunnan Yunwei Co Ltd Class A
SHG:600725
|
-0.044x |
|
Jamna Auto Industries Limited
NSE:JAMNAAUTO
|
0.246x |
|
CARE Ratings Limited
NSE:CARERATING
|
0.029x |
|
Optotech Corp
TW:2340
|
-0.010x |
Annual Cash Flow Conversion Efficiency for Neurogene Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Neurogene Inc from 2011 to 2025. Review Neurogene Inc (NGNE) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $264.89 Million | $-77.17 Million | -0.291x | -28.08% |
| 2024-12-31 | $310.38 Million | $-70.60 Million | -0.227x | +17.71% |
| 2023-12-31 | $186.02 Million | $-51.42 Million | -0.276x | +48.39% |
| 2022-12-31 | $98.63 Million | $-52.82 Million | -0.536x | -206.05% |
| 2021-12-31 | $-91.88 Million | $-46.40 Million | 0.505x | +492.96% |
| 2020-12-31 | $191.22 Million | $-24.57 Million | -0.129x | -18.29% |
| 2019-12-31 | $141.69 Million | $-15.39 Million | -0.109x | +75.00% |
| 2018-12-31 | $72.67 Million | $-31.58 Million | -0.435x | +3.91% |
| 2017-12-31 | $98.89 Million | $-44.72 Million | -0.452x | -116.43% |
| 2016-12-31 | $144.66 Million | $-30.23 Million | -0.209x | -11.77% |
| 2015-12-31 | $108.42 Million | $-20.27 Million | -0.187x | +62.05% |
| 2014-12-31 | $36.15 Million | $-17.81 Million | -0.493x | -218.24% |
| 2013-12-31 | $51.28 Million | $-7.94 Million | -0.155x | +98.13% |
| 2012-12-31 | $874.03K | $-7.23 Million | -8.275x | -625.11% |
| 2011-12-31 | $8.59 Million | $-9.80 Million | -1.141x | -- |
About Neurogene Inc
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disea… Read more